Gastrointestinal Agents Market by Type, Disease Type, Route of Administration, Distribution Channel, End-User

Description

List of Tables

[195 Pages Report] The Gastrointestinal Agents Market size was estimated at USD 57.26 billion in 2023 and expected to reach USD 60.06 billion in 2024, at a CAGR 4.97% to reach USD 80.47 billion by 2030.

Gastrointestinal agents are a category of medications designed to treat various conditions that affect the gastrointestinal tract, which includes the stomach and intestines. These conditions range from acid reflux and ulcers to irritable bowel syndrome and Crohn's disease. The primary role of these agents is to improve gut function, relieve symptoms, and manage or cure underlying GI disorders. The rise in gastrointestinal diseases around the world, including conditions such as gastroesophageal reflux disease, peptic ulcers, and inflammatory bowel disease (IBD), drives the need for effective gastrointestinal agents. Growing awareness about gastrointestinal health and improved access to healthcare services in developing regions also contribute to the expanded use of GI agents. High treatment costs and drug resistance issues with gastrointestinal agents hamper the market growth. Ongoing research and development in gastroenterology led to introduction of more effective and safer drugs, which are expected to create opportunities for gastrointestinal agent market.

KEY MARKET STATISTICS
Base Year [2023]	USD 57.26 billion
Estimated Year [2024]	USD 60.06 billion
Forecast Year [2030]	USD 80.47 billion
CAGR (%)	4.97%

Regional Insights

In the Americas, the gastrointestinal agents market is highly developing due to advanced healthcare systems, high awareness of gastrointestinal disorders, and substantial investments in healthcare. The higher prevalence of gastrointestinal diseases and the strong presence of pharmaceutical companies create a platform for the gastrointestinal agents market. In South America, improvements in healthcare infrastructure and increased health insurance coverage are gradually boosting the market. The APAC region is seeing rapid growth in the gastrointestinal agents market driven by increasing population, rising healthcare expenditures, and growing awareness of gastrointestinal disorders. Countries such as Japan, China, and India are leading this growth due to their large populations and increasing middle class, which has better access to healthcare services. Additionally, Asia-Pacific is experiencing a shift towards Western diets, increasing the prevalence of gastrointestinal issues. Europe is a major region in the global gastrointestinal agents market, with advanced healthcare systems and a high prevalence of gastrointestinal diseases. Regulatory support and the presence of major pharmaceutical companies also contribute to the growth of this market. The Gulf Cooperation Council (GCC) countries show higher market penetration due to better healthcare infrastructure, while other parts of Africa are emergent markets with limited access to healthcare.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Gastrointestinal Agents Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Growing prevalence of gastrointestinal disorders across the globe
- Educational campaigns about gastrointestinal health and available treatments
- Favorable changes in health insurance coverage and reimbursement policies

Market Restraints
- Disruptions in the supply of raw materials required for drug manufacturing

Market Opportunities
- Government approvals for new therapeutic agents to treat gastrointestinal disorders
- Ongoing research and development aimed at innovative drug formulations and delivery systems

Market Challenges
- Side effects associated with gastrointestinal drugs and supplements

Market Segmentation Analysis
- Type: Growing usage of dietary supplements with an increasing number of health-conscious consumers
- End-User: High potential of gastrointestinal agents across hospitals & clinics as part of initial treatment and ongoing management plans for patients

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Gastrointestinal Agents Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Gastrointestinal Agents Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Introduction of Calm & Focus: A Zembrin and GABA-Based Dietary Supplement by PLT Health Solutions

PLT Health Solutions, in collaboration with Now, has launched 'Calm & Focus with Zembrin & GABA', a new dietary supplement formulated for cognitive enhancement. This product incorporates Zembrin, a patented extract of the South African plant Sceletium tortuosum, traditionally used by the Khoi-San people for mood enhancement and stress reduction. The supplement is designed to offer rapid benefits, promoting alertness, serene focus, and improved mental functionality through the combined effects of Zembrin and GABA, ensuring a balanced approach to stress management and cognitive support. [Published On: 2023-11-17]

Innovative Women's Health Probiotics Launched by Designs for Health

Designs for Health has introduced two new products tailored for women's health across different life stages. The first, ProbioMed Women, is a daily probiotic supplement containing 25 billion CFUs from 10 clinically researched strains. This formulation is engineered to support vaginal pH, microflora balance in the vagina, and gastrointestinal microbial equilibrium. [Published On: 2023-08-17]

Market Introduction of Wonderbelly Antacid with Exclusive Flavor at Target Stores

Wonderbelly, an Austin, Texas-based company, is launching its FDA-regulated Wonderbelly Antacid in select Target stores, featuring a Target-exclusive flavor, Fruity Cereal. The product line, designed to alleviate heartburn, acid indigestion, and sour stomach, includes Strawberry Milkshake and Watermelon Mint flavors. This introduction aims to attract customers seeking effective over-the-counter digestive solutions with appealing flavor options. [Published On: 2023-03-27]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Gastrointestinal Agents Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Agents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, American Health, Amway Corporation, Archer-Daniels-Midland Company, ARKOPHARMA Laboratories, Company Limited, Bayer AG, Biomedical Research Laboratories, LLC, DuPont de Nemours, Inc., Dymatize Enterprises LLC, FANCL Corporation, Glanbia PLC, GlaxoSmithKline PLC, Herbalife Nutrition Ltd., Himalaya Wellness Company, Nature's Sunshine Products, Inc., Nestle S.A, Nutraceutical International Corporation, NutraScience Labs, Otsuka Holdings Co. Ltd., Pfizer Inc., Pragati Biocare Pvt. Ltd.,, Procter & Gamble Health Limited, Pure Encapsulations, LLC., Sabinsa Corporation, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Dietary Supplements
- Drugs
  - Antacids
  - Anti-diarrheal Agents
  - Anti-emetics
  - H2 Blockers
  - Laxatives
  - Proton Pump Inhibitors
Disease Type
- Constipation
- Diarrhea
- Gastroesophageal Reflux Disease
- Inflammatory Bowel Disease
- Irritable Bowel Syndrome
- Peptic Ulcer Disease

Route of Administration
- Oral
- Parenteral
- Rectal

Distribution Channel
- Offline Pharmacies
- Online Pharmacies

End-User
- Homecare
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-CB04E056533F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of gastrointestinal disorders across the globe
  - 5.1.1.2. Educational campaigns about gastrointestinal health and available treatments
  - 5.1.1.3. Favorable changes in health insurance coverage and reimbursement policies
- 5.1.2. Restraints
  - 5.1.2.1. Disruptions in the supply of raw materials required for drug manufacturing
- 5.1.3. Opportunities
  - 5.1.3.1. Government approvals for new therapeutic agents to treat gastrointestinal disorders
  - 5.1.3.2. Ongoing research and development aimed at innovative drug formulations and delivery systems
- 5.1.4. Challenges
  - 5.1.4.1. Side effects associated with gastrointestinal drugs and supplements
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing usage of dietary supplements with an increasing number of health-conscious consumers
- 5.2.2. End-User: High potential of gastrointestinal agents across hospitals & clinics as part of initial treatment and ongoing management plans for patients
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Gastrointestinal Agents Market, by Type

6.1. Introduction
6.2. Dietary Supplements
6.3. Drugs

7. Gastrointestinal Agents Market, by Disease Type

7.1. Introduction
7.2. Constipation
7.3. Diarrhea
7.4. Gastroesophageal Reflux Disease
7.5. Inflammatory Bowel Disease
7.6. Irritable Bowel Syndrome
7.7. Peptic Ulcer Disease

8. Gastrointestinal Agents Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Rectal

9. Gastrointestinal Agents Market, by Distribution Channel

9.1. Introduction
9.2. Offline Pharmacies
9.3. Online Pharmacies

10. Gastrointestinal Agents Market, by End-User

10.1. Introduction
10.2. Homecare
10.3. Hospitals & Clinics

11. Americas Gastrointestinal Agents Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Gastrointestinal Agents Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Gastrointestinal Agents Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Introduction of Calm & Focus: A Zembrin and GABA-Based Dietary Supplement by PLT Health Solutions
- 14.3.2. Innovative Women's Health Probiotics Launched by Designs for Health
- 14.3.3. Market Introduction of Wonderbelly Antacid with Exclusive Flavor at Target Stores
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio